Cannabinoids are a collection of naturally occurring compounds that are situated in the marijuana plant (cannabis sativa). Cannabidiol (CBD) is the main chemical within the cannabis plant and it is said by the wide scientific community that it has anti inflammatory effects when induced into animal cells. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said to have a psychotropic effect. Cannabinoid receptors (CB1 and CB2) are located in the endocannabinoid system and gives cannabinoids power to bind and thrive in the body. This paper will look at how the cannabinoid receptors 1 and 2 can be activated to treat non-Hodgkin lymphoma.
Here is the full scientific article if you wish to download it.
Endogenous and synthetic cannabinoids give off antiproliferative and proapoptotic impacts in different strands of cancer and in mantle cell lymphoma (MCL). In this review, the expression of cannabinoid receptors type 1 and type 2 (CB1 and CB2) were evaluated in non‐Hodgkin lymphomas. In functional research using MCL, Burkitt lymphoma (BL), chronic lymphocytic leukemia (CLL) and plasma cell leukemia cell lines, cannabinoids induced cell death only in MCL and CLL cells, which overexpressed both cannabinoid receptors, but not in BL. In a different treatment with a selective cannabinoids, the induction caused a massive reduction of tumor size in mice with human MCL. Together, the conclusion of this research indicates that therapies using cannabinoid receptor agonists will have effectiveness in decreasing tumor conditions in severe lymphoma overexpressing CB1 and CB2.
This studies conclusions display that CB1 and CB2 are expressed in numerous profiles of non‐Hodgkin lymphomas. The greatly dynamical expression in well‐described lymphoma profiles indicates that cannabinoid receptors might possibly be go to places for specific therapeutic interventions. Treatment with the stable endocannabinoid induces cell death in tumor cell lines from MCL and CLL, expressing greater amounts of both CB1 and CB2 when paralleled with reactive lymphoid tissue.